Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


ACIP Shies Away From COVID-19 Vaccine Comparative Efficacy And Safety Evaluations

The CDC panel’s mandate is to make recommendations for each specific vaccine brought forward, not ‘comparing two, three or four vaccines, and coming up with specific recommendations for each one independent of the other,’ chairman Jose Romero says as ACIP recommends use of Janssen’s COVID-19 vaccine under EUA.

Vaccines Coronavirus COVID-19 Advisory Committees

2020 Deal-Making Snapshot: A Busy Year For Bolt-Ons

Looking back at the deal landscape of 2020, large-scale deals were overtaken by smaller transactions, though volume was up, driven by pandemic-related business.

Deals M & A Business Strategies

Bayer Ponders Road Less Traveled And Trip Savings In Pandemic

Like most CEOs in pharma, Bayer chief Werner Baumann was constantly on the move but "since the middle to the end of the first quarter last year, I haven't traveled at all."

Coronavirus COVID-19 Strategy Leadership

Coronavirus Spotlight

SARS-CoV-2 Variants And Current Vaccines: “It’s Not All Or Nothing”

Experts including renowned virologist Peter Piot, FDA’s Peter Marks and CEPI’s Richard Hatchett discussed multiple dimensions pertaining to coronavirus variants and existing vaccines at a recent conference, noting enhanced post-deployment surveillance is underway in the US. While there’s no need to panic for every variant that emerges, equitable access to vaccines is critical to ensure that gains made over last year are not undone, they said.


Coronavirus COVID-19 Vaccines

Rolling Coverage Of The Coronavirus Outbreak And The Biopharma Industry's Response Is Here.


Recent Tweets from Scrip


 

Infographics

Predicting Success: The Easiest, And Hardest Routes To Market

A new analysis from BIO, Informa Pharma Intelligence and QLS looks at clinical drug development activity from the past decade, looking at the most (and least) successful areas. Infographic depicts key trends and details.

The Race To Vaccinate The World Against COVID-19

Our graphic tracker of key developments from emergency authorized vaccines, the global roll-out, and late-stage vaccine candidates.

Infographic: Cancer Deal-Making In 2020

Despite the COVID-19 pandemic, 2020 has seen a hectic pace of cancer deal-making, including the two largest biopharma M&A deals of the year and 23 with upfront value of at least $100m.

Commercial Explore this Topic

Set Alert for Commercial

Merck KGaA Bags Exclusive Rights To Develop, Sell Debiopharm’s Xevinapant

Germany’s Merck has licensed exclusive rights to develop and sell Debiopharm’s potential first-in-class inhibitor of apoptosis proteins (IAP) antagonist, targeting head and neck cancers.

Commercial Companies

Roche Gets Long-Awaited Green Light For COVID-19 Cocktail In EU

Key committee was asked to fast-track a decision on the antibody cocktail, but lack of mortality data could mean patchy uptake seen in US repeated in the EU.

BioPharmaceutical Commercial

AstraZeneca Cashes In Moderna Chips

The firms' messenger RNA alliance inked back on 2013 is still very much ongoing but AstraZeneca decided to sell its considerable stake in the high-profile biotech to help finance its own pipeline.

Deals Strategy

Stockwatch: The Pandemic – Where Generics Failed To Reign

If demand-side pressures on the life science sector were not enough, generic price erosion, debt repayment and extended restructurings are worsening the generic pharmaceutical investment proposition.

Companies Generic Drugs

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.

Commercial Approvals

COVID-19 Vaccine Gives Moderna $18bn Launchpad Into HIV Vaccine, Cancer Therapies

A rush of additional orders from countries around the world has boosted the company’s prospects, and fueled its ambitions beyond COVID-19.

Companies Commercial
See All

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

SARS-CoV-2 Variants And Current Vaccines: “It’s Not All Or Nothing”

Experts including renowned virologist Peter Piot, FDA’s Peter Marks and CEPI’s Richard Hatchett discussed multiple dimensions pertaining to coronavirus variants and existing vaccines at a recent conference, noting enhanced post-deployment surveillance is underway in the US. While there’s no need to panic for every variant that emerges, equitable access to vaccines is critical to ensure that gains made over last year are not undone, they said.

Coronavirus COVID-19 Vaccines

GSK’s Dostarlimab Gets EU Nod For Endometrial Cancer

While its NDA languishes at the US Food and Drug Administration, the EMA’s CHMP has said yes to dostarlimab’s marketing in the EU for endometrial cancer.

Approvals Companies

Amid Coronavirus Variants, WHO Urges Continued Vaccination

As vaccine makers tackle SARS-CoV-2 variants, WHO’s Chief Scientist feels it’s important to continue immunization programs with existing vaccines. Meanwhile, the rollouts mean the safety and efficacy landscape is set to change, said participants at a recent meet

Coronavirus COVID-19 Policy & Regulation
See All

Research & Development Explore this Topic

Set Alert for Research & Development

Merck KGaA Bags Exclusive Rights To Develop, Sell Debiopharm’s Xevinapant

Germany’s Merck has licensed exclusive rights to develop and sell Debiopharm’s potential first-in-class inhibitor of apoptosis proteins (IAP) antagonist, targeting head and neck cancers.

Commercial Companies

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Respiratory Clinical Trials

Pipeline Watch: Phase III Readouts For Dry Eye, Menopause

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All
UsernamePublicRestriction

Register